Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2253
https://www.valueinhealthjournal.com/article/S1098-3015(16)33619-1/fulltext
Title :
Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33619-1&doi=10.1016/j.jval.2016.09.2253
First page :
A740
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2136